Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
August 2022
Incident and Recurrent Herpes Zoster for First-Line bDMARD and tsDMARD Users in Seropositive Rheumatoid Arthritis Patients: A Nationwide Cohort Study
Arthritis Res Ther. 2022;24(1):180
Herpes zoster (HZ) risk is significantly increased in seropositive RA patients with a history of HZ after the initiation of bDMARDs or tsDMARD. It is now well known that the incidence and recurrence of HZ are quite common in patients with RA in real-world clinical settings, yet there is limited evidence regarding bDMARD-dependent HZ risk among patients with a history of HZ prior to bDMARD use.